Lunch with Annabel | HZNP Message Board Posts

Horizon Pharma, Inc.

  HZNP website

HZNP   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1695 of 1699  at  9/17/2019 10:47:49 AM  by

Drummer1517


 In response to msg 1694 by  drugfree
view thread

Re: Lunch with Annabel

Thanks for posting this link. Annabel is one of the few analysts that really understands HZNP's potential, noting that it is on the precipice of breaking through the malaise that has been plaguing the company's stock price for the past few months. Even great news does not push the needle very much. Part of the problem may be weak longs that are trading the stock for a quick profit as opposed to long term investors that agree with Annabel's view of the company. A $35 price target is fairly conservative given that K and T (when approved) are projected to generate combined annual peak sales of $1.5 billion. Those sales when combined with primary care sales of about $300 million per year and historical other rheumatology sales of about $500 million results in about $2.3 billion in annual revenue. HZNP has also put together a team to promote T once approved---the company is executing very well. What's' not to like...


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 152
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
1696 Re: Lunch with Annabel geringerart 0 9/18/2019 4:55:12 AM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...